Shire hits the road with ulcerative colitis patient awareness program

Share this article:

Shire Pharmaceuticals is hitting “the road” as part of a new unbranded education campaign for patients with ulcerative colitis (UC), complete with live events in 10 cities.

Shire developed the “On the Road Again” campaign as a response to results of its series of company-sponsored surveys completed in 2007 illustrating the challenges that exist for UC patients including communication gaps with physicians, medication compliance and other life disruptions. Approximately 700,000 people in the US are afflicted with UC. 

“The ‘On the Road Again' program is intended to empower people with UC across the country and provide them with the knowledge and tools necessary to better manage their disease and regain control of their lives,” explained Mike Yasick, SVP and gastrointestinal global business unit leader at Shire.

The campaign will feature live education event tour stops this spring in Miami, Houston, Atlanta, Chicago, New York, Minneapolis, Philadelphia, Pittsburgh, Los Angeles and Long Island, NY. Each event will include a dietician, a gastroenterologist, a social worker or health psychologist, and an online health information professional. These experts will discuss UC and the role of diet, treatment options and building an online UC community, Shire said.

Shire currently markets UC treatments Lialda (mesalamine) and Pentasa (mesalamine).

In addition to this spring's live event tour, Shire has also launched http://www.roadtouclearning.com/, an online tour companion that features the “On the Road Again” event schedule, speaker bios, and registration and condition information.

Share this article:

Email Newsletters

More in News

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Fabry disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.

Five things for pharma marketers to know: Wednesday, August 20

Five things for pharma marketers to know: Wednesday, ...

Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma ...